N/A N=14 Cardiovascular Rehabilitation Early After Stroke Using Feedback-controlled Robotics-assisted Treadmill Exercise
Stroke · Cardiovascular Diseases
Primary: Peak Oxygen Uptake (V'O2peak) — 1461; 1494 mL/min — p=0.53
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=127 Responses of Myocardial Ischemia to Escitalopram Treatment
Myocardial Ischemia
Primary: Percentage of Participants With an Absence of Mental Stress-induced Myocardial Ischemia (MSIMI) During the 3 Mental Stressors — 34.2; 17.5 percentage of participants
Phase 2 N=72 Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer
Breast Cancer
Primary: Five-Year Relapse-free Survival — 47; 55 percentage of participants
N/A N=6,700 Adult and Paediatric Patient Radiation Doses From Multidetector Row Computed Tomography Scans: a National Survey
Cancer
Primary: Value of Mean Volumetric Computed Tomography Dose Index (CTDI Vol) for Head CT Examinations. — 64; 28.7 mGy
Phase 2 N=94 Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
HIV-1 Infection
Primary: Difference Between [Change From Week 24 to Week 44] and [Change From Baseline to Week 20] in log10 IL-6 — -0.08; -0.08 log10 pg/mL — p=0.94
Phase 3 N=579 Chemopreventive Therapy for Malaria in Ugandan Children
Malaria
Primary: Incident Malaria Cases Per Person Year at Risk in HIV-unexposed Participants — 6.95; 6.73; 5.21; 3.02 Episode per person year at risk — p=0.57
Phase 2 N=487 Study of AERAS-402 in Healthy Infants
Tuberculosis
Primary: Adverse Events Collected Per Subject — 94.2; 96.1; 100.0; 100.0 percentage of subjects with an AE
N/A N=16 Influence of OATP1B1 and CYP2C9 Genotypes on the Pharmacokinetics of Bosentan Before and During Clarithromycin
Drug Interactions
Primary: AUC — 11900; 6830; 25500 h*ng/ml
Phase 2 N=316 A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection
Hepatitis C, Chronic
Primary: Percentage of Participants in Each Treatment Group With Sustained Virologic Response 12 Weeks Post-treatment — 90.9; 95.2; 90.0; 100 Percentage of participants — p=0.381
Phase 3 N=315 A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma
Multiple Myeloma
Primary: Overall Survival — 10.0; 10.2 months — p=0.4172
Phase 2 N=307 A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Primary: Progression-free Survival — 232; 245 days
Phase 2 N=215 Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.
HIV Infections · Cognition Disorders
Primary: Change in Global Neurocognitive Performance z Score From Baseline — 0.24; 0.16 z score — p=0.18
Phase 3 N=50 Therapy to Prevent Sexual Pain in Breast Cancer Survivors
Vulvodynia · Dyspareunia · Breast Cancer
Primary: Prevention of Entry Dyspareunia With Non-hormonal Therapy — 5.3; 1.04; NA; 0.57 Units on a scale — p=0.0149
Phase 3 N=250 Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis
Psoriasis · Psoriatic Arthritis
Primary: Percentage of Participants Who Achieved a 75% Improvement (Response) in the Psoriasis Area Severity Index (PASI-75) for the Comparison Between Apremilast and Placebo at…
Phase 2 N=16 5-Azacytidine Prior to Allogeneic Stem Cell Transplant in High Risk Myelodysplastic Syndrome
Myelodysplastic Syndrome
Primary: One Year Overall Survival of Allogeneic Transplant Recipients After Transplantation — 50 percentage of participants